The Availability Of Essential Parkinson's Disease Medications In The Public And Private Sectors And The Suitability Of Storage Conditions For Medications In Nafusa Mountain, Libya
DOI:
https://doi.org/10.65405/.v10i37.517Keywords:
: Parkinson’s disease, essential medications, biperiden, levodopa/carbidopaAbstract
In the recent years, parkinson’s disease has been distributed widely over the world
specifically among elderly people. The major aim of this research is find out the availability
rates for the essential parkinson’s disease medications (PDMs) as well as studying the
suitability of storage conditions of medications in the major cities of Nafusa Mountain,
Libya. A survey was completed after a field visit to the major hospitals and to the biggest
private pharmacies in the area of study. The results showed that the essential PDMs were not
available in the public sector. In the private sector, the highest availability rate were 66.66%
in Gharyan pharmacy. The availability rates of biperiden and levodopa/carbidopa were 10%
and 20% respectively in the private sector. Regarding the suitability of storage conditions of
medicines in the dispensing area, the storage conditions were 100% compliance in AlAwainiya hospital (public sector), Jadu hospital (public sector), Jadu pharmacy (private
sector) and Al-Zintan pharmacy (private sector). It is recommended to address the root causes
of the low availability of essential PDMs in both sectors. In additions, try to improve the
storage conditions for medicines in the dispensing areas.
Downloads
References
- Cho. H.J, “Carbidopa/Levodopa - Uses, Side Effects, and More”, WebMD,
2024.
- Fothergill-Misbah, N., Hooker, J., Kwasa. J., Walker, R. (2024). Access to
Medicines for Parkinson's Disease in Kenya: A Qualitative Exploration.
Movement Disorders Clinical Practice, 11 (11), 1373-1378. doi:
10.1002/mdc3.14192.
- Goh, ZHK., Cheong, JLY., Marras, C., Tanne,. CM., Kaste,. M., Korczyn,
AD., Chahine, L., Lo, R., Noycem AJ. (2022). Surveying Global Availability
of Parkinson's Disease Treatment. Journal of Parkinson’s Disease, 12 (3), 1023-
1034. https://doi.org/10.3233/JPD-213006
- Guillermo, GJ., Urbano, SC.,. Angélica, BM., and Johana, SCB. (2018).
Availability of Drugs for the Treatment of Parkinson’s Disease, Pharmacy
Network in the Municipality Riobamba. Journal of Rheumatology and Arthritic
Diseases, 3(2), 1–4. https://doi.org/10.15226/2475-4676/3/2/00139.
- Hamid, E., Ayele, BA., Massi, DG., Ben Sassi, S., Tibar, H., Djonga, EE., ElSadig, SM., Amer. El Khedoud, W., Razafimahefa, J., Kouame-Assouan, AE.,
Ben-Adji, D., Lengané, YTM., Musubire, AK., Mohamed.. MH., Phiri, TE.,
Nestor, N., Alwahchi, WA., Neshuku, SN., Ocampo, C., Sakadi, F., Maidal,
MA., Ngwende, GW., Hooker, J., Okeng',. K., Charway-Felli, A., Atadzhanov,
M., Carr. J., Okubadejo, NU., Shalas,. A. (2021). Availability of Therapies and
Services for Parkinson's Disease in Africa: A Continent-Wide Survey.
Movement Disorders, 26 (10), 2393-2407.
- Kostelnik A, Cegan A, Pohanka M. Anti-Parkinson Drug Biperiden Inhibits
Enzyme Acetylcholinesterase. Biomed Research International., 2017
- Mokaya, J., Dotchin, CL., Gray, WK., Hooker, J., Walker, RW. (2016). The
Accessibility of Parkinson's Disease Medication in Kenya: Results of a National
Survey. Movement Disorders, 3 (4), 376-381.
https://doi.org/10.1002/mdc3.12294
- Morales, L. (2023). What is the connection between dopamine and Parkinson's
disease?. MedicalNewsToday,
المجلد )10(، العدد )37(، )نوفمبر2025( ردمد: 3014-6266 :ISSN 3-1301
- Okubadejo, NU., Ojo, OO., Wahab, KW., Abubakar, SA., Obiabo, OY.,
Salawu, FK., Nwazor, EO., Agabi, OP., Oshinaike, OO. (2019). A Nationwide
Survey of Parkinson's Disease Medicines Availability and Affordability in
Nigeria. Movement Disorders Clinical Practice, 6 (1), 27-33.
- Patel, T., Chang,. F. (2014). Parkinson’s disease guidelines for pharmacist.
Canadian Pharmacists Journal, 147 (3), 161–170.
https://doi.org/10.1177/1715163514529740
- Sakdisornchai, K., Sringean, . J., Jitkritsadakul, O., panyakaew, P.,
Bhidayasiri, R. (2018). Availability of anti-Parkinsonian drugs in Thailand.
International Parkinson and movement disorder society, 32 (2).
- WHO. (March 2017). WHO Model List of Essential Medicine 20th List.
- WHO. (2007). WHO Operational package for assessing, Monitoring and
evaluating country pharmaceutical situations. Guide for coordinators and data
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
